Back to today’s briefing

Story perspectives

Bristol Myers' Opdualag Fails Melanoma Trial, Eyes Lung Cancer Hope

2/14/2025

50 9

Summary

Story summary

Bristol Myers Squibb's Opdualag, designed to combat melanoma, stumbled in a Phase 3 trial, showing no improvement in preventing cancer recurrence for stage III and IV patients compared to Opdivo alone. Yet, the company holds onto hope for Opdualag's promise in treating non-small cell lung cancer, anticipating robust sales ahead.

1 of 1

Story summary

Bristol Myers Squibb's Opdualag, designed to combat melanoma, stumbled in a Phase 3 trial, showing no improvement in preventing cancer recurrence for stage III and IV patients compared to Opdivo alone. Yet, the company holds onto hope for Opdualag's promise in treating non-small cell lung cancer, anticipating robust sales ahead.